Norah Henry
机构: Professor of Internal Medicine, University of Michigan
每年引用次数
引用次数
引用: 14,355
H-指数: 52
I10-指数 : 138
出版物: 363
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial
Cesar A. Santa-Maria , Aditya Bardia , Amanda L. Blackford , Claire Snyder
Breast Cancer Research and Treatment 171 ( 1) 121 -129
4
2018
Adjuvant endocrine therapy in premenopausal women with breast cancer
Kadakia Kc , Henry Nl
Clinical advances in hematology & oncology 13 ( 10) 663 -672
12
2015
Abstract P3-08-04: Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer
M Tanioka , JS Parker , LN Henry , S Tolaney
Cancer Research 79
2019
Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer
M Tanioka , JS Parker , LN Henry , S Tolaney
CANCER RESEARCH 79 ( 4)
2019
Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy
Craig J. Galbán , Bing Ma , Dariya Malyarenko , Martin D. Pickles
PLOS ONE 10 ( 3)
33
2015
The Effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: A longitudinal study.
Jamie Caughran , Tom M. Braun , Tara M. Breslin , Daniel R. Smith
Breast Journal 24 ( 5) 730 -737
2
2018
Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105).
Anna Moseley , Kathryn B Arnold , Grace Hillyer , Julie Gralow
Journal of Clinical Oncology 38 12019 -12019
2
2020
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Mehra Golshan , Constance T Cirrincione , William M Sikov , Lisa A Carey
Breast Cancer Research and Treatment 160 ( 2) 297 -304
64
2016
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
Vinicius F Calsavara , Norah L Henry , Ron D Hays , Sungjin Kim
Cancer Prevention Research 16 ( 11) 631 -639
2023
Management of patients with muscle-invasive and metastatic bladder cancer
Gary MacVicar , Maha Hussain , N Lynn Henry
Oncology 19 ( 10) 1333 -1342
6
2005
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias.
Maryam B Lustberg , N Lynn Henry , Patrick M Schnell
JNCI Cancer Spectrum 5 ( 2)
2021
Patient Reported Outcomes and Long-Term Non-Adherence to Aromatase Inhibitors.
Julie R Gralow , Kathryn B Arnold , Dawn L Hershman , Joseph M Unger
Journal of the National Cancer Institute
1
2021
Disparities in Cardiovascular Disease Risk Among Hispanic Breast Cancer Survivors in a Population-Based Cohort.
Christina Porucznik , Mia Hashibe , Mia Hashibe , N Lynn Henry
JNCI Cancer Spectrum 5 ( 2)
2021
Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.
N Lynn Henry , Daniel L Hertz , Yihan Sun , Kathleen A Stringer
Cancer Chemotherapy and Pharmacology
2021
Adjuvant systemic therapy for elderly women with breast cancer
N Lynn Henry , Kathleen M Diehl , Daniel F Hayes
Women's Health 2 ( 1) 75 -87
2
2006
Abstract P6-08-50: Clinical predictors of long-term survival in Her2-positive (HER2+) metastatic breast cancer (MBC)
Pooja Murthy , Kelley M Kidwell , Dafydd G Thomas , Jennifer J Griggs
Cancer Research 75
1
2015
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
Jacqueline M Dempsey , Kelley M Kidwell , Christina L Gersch , Andrea M Pesch
Pharmacogenomics 20 ( 8) 571 -580
1
2019
Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.
Daniel L Hertz , N Lynn Henry , James M Rae
Pharmacogenomics 18 ( 5) 481 -499
14
2017
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Yongzhen Chen , Fang Fang , Kelley M Kidwell , Kiran Vangipuram
Pharmacogenomics 21 ( 12) 841 -851
1
2020
Aromatase inhibitor-associated musculoskeletal pain: taking ‘AIM’ at a symptom in breast cancer survivors
N Lynn Henry
Pain management 1 ( 3) 191 -193
2011